Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Change in Taxes (2018 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Taxes for 8 consecutive years, with $955000.0 as the latest value for Q4 2025.

  • Quarterly Change in Taxes rose 132.74% to $955000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.7 million through Dec 2025, down 15.45% year-over-year, with the annual reading at -$2.7 million for FY2025, 15.45% down from the prior year.
  • Change in Taxes hit $955000.0 in Q4 2025 for Ligand Pharmaceuticals, up from -$864000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $12.0 million in Q1 2022 to a low of -$16.7 million in Q4 2022.
  • Historically, Change in Taxes has averaged -$39950.0 across 5 years, with a median of -$908500.0 in 2024.
  • Biggest YoY gain for Change in Taxes was 1018.75% in 2022; the steepest drop was 304.96% in 2022.
  • Year by year, Change in Taxes stood at $8.1 million in 2021, then crashed by 304.96% to -$16.7 million in 2022, then skyrocketed by 145.53% to $7.6 million in 2023, then plummeted by 138.39% to -$2.9 million in 2024, then soared by 132.74% to $955000.0 in 2025.
  • Business Quant data shows Change in Taxes for LGNDZ at $955000.0 in Q4 2025, -$864000.0 in Q3 2025, and -$2.4 million in Q2 2025.